Haddad, Tariq Sami, Lugli, Alessandro, Aherne, Susan, Barresi, Valeria, Terris, Benoît, Bokhorst, John-Melle, Brockmoeller, Scarlet Fiona, Cuatrecasas, Miriam, Simmer, Femke, El-Zimaity, Hala, Fléjou, Jean-François, Gibbons, David, Cathomas, Gieri, Kirsch, Richard, Kuhlmann, Tine Plato, Langner, Cord, Loughrey, Maurice B., Riddell, Robert, Ristimäki, Ari, and Kakar, Sanjay
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet methods for its assessment have varied widely. In an effort to standardize its reporting, a group of experts met in Bern, Switzerland, in 2016 to reach consensus on a single, international, evidence-based method for tumor budding assessment and reporting (International Tumor Budding Consensus Conference [ITBCC]). Tumor budding assessment using the ITBCC criteria has been validated in large cohorts of cancer patients and incorporated into several international colorectal cancer pathology and clinical guidelines. With the wider reporting of tumor budding, new issues have emerged that require further clarification. To better inform researchers and health-care professionals on these issues, an international group of experts in gastrointestinal pathology participated in a modified Delphi process to generate consensus and highlight areas requiring further research. This effort serves to re-affirm the importance of tumor budding in colorectal cancer and support its continued use in routine clinical practice. [ABSTRACT FROM AUTHOR]